NCT03439189View on ClinicalTrials.gov

Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14

CompletedINTERVENTIONAL
Enrollment

343

Participants

Timeline

Start Date

August 28, 2016

Primary Completion Date

April 8, 2019

Study Completion Date

May 13, 2019

Conditions
NASH - Nonalcoholic SteatohepatitisCirrhosisPortal Hypertension
Interventions
COMBINATION_PRODUCT

Methacetin Breath Test

A breath analyzer will be used to measure changes in carbon-12 to carbon-13 ratio as a result of metabolism of the Methacetin substrate before and after treatment.

DRUG

Emricasan

Investigational drug for NASH treatment in Main Conatus protocol

DRUG

Placebo oral capsule

Placebo versus emricasan in Conatus NASH treatment trial

Trial Locations (1)

92118

Hopital Beaujon, Clichy

Sponsors
All Listed Sponsors
collaborator

Conatus Pharmaceuticals Inc.

INDUSTRY

lead

Meridian Bioscience, Inc.

INDUSTRY

NCT03439189 - Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14 | Biotech Hunter | Biotech Hunter